Patent application on use of insulin sensitisers in senile dementia and memory loss receives notice of allowance
26 February 2009
A notice of allowance in Europe has been received by the University of Buckingham collaborators, Mindset Biopharmaceuticals (USA) Inc, for patent applications describing the use of insulin sensitiser drugs for the prevention and treatment of memory loss. Drugs of this type include Rosiglitazone and Pioglitazone, which have been approved for the treatment of type II diabetes mellitus. There is growing evidence that glucose utilisation in the brain of older people becomes impaired and this is especially so in those suffering from senile dementia and other forms of memory loss. This reduced glucose utilisation results from resistance to the action of insulin in the brain and insulin sensitiser drugs such as Rosiglitazone and Pioglitazone restore the ability of brain cells to properly use glucose. Several clinical studies have shown that the insulin sensitiser drug Rosiglitazone improves learning and memory.
Professor Mike Cawthorne, Director of Metabolic Research at the Clore Laboratory, University of Buckingham is the co-inventor of the patent with Dr Daniel Chain of Mindset. Mike Cawthorne, who led the research team that originally discovered Rosiglitazone as an insulin sensitiser for diabetes treatment, commented “If insulin sensitiser drugs such as Rosiglitazone continue to show efficacy in large scale trials as they have done in smaller published trials, then it will surely herald an important new therapeutic option to improve the quality of life for people all over the world who suffer from various dementias as well as normal age-related memory loss”.
Dr Daniel Chain, the founder of Mindset and Company President is the son of the late Professor Anne Beloff-Chain, founder of the Clore Laboratory, and nephew of Lord Beloff, first Principal of the University of Buckingham.